Cardiovascular risk in a first-episode psychosis sample: A 'critical period' for prevention?

Schizophrenia Research

Volumn 127, Issue 1-3, 2011, Pages 257-261

  Phutane, Vivek H ^a   Tek, Cenk ^a   Chwastiak, Lydia ^a   Ratliff, Joseph C ^a   Ozyuksel, Banu ^a   Woods, Scott W ^a   Srihari, Vinod H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cardiovascular mortality; Cardiovascular risk; Critical period; Early intervention; First episode psychosis

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; GLUCOSE; HALOPERIDOL; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

ADULT; ARTICLE; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; EARLY INTERVENTION; FEMALE; FIRST EPISODE PSYCHOSIS; GLUCOSE BLOOD LEVEL; HEALTH SURVEY; HEMOGLOBIN BLOOD LEVEL; HIGH RISK POPULATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PHYSICAL EXAMINATION; PRIMARY PREVENTION; PRIORITY JOURNAL; PSYCHOSIS; RISK ASSESSMENT; SMOKING; UNITED STATES;

ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; CRITICAL PERIOD (PSYCHOLOGY); CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; YOUNG ADULT;

EID: 79952313121     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2010.12.008     Document Type: Article

References (41)

1. Alvarez-Jimenez M., Martinez-Garcia O., Perez-Iglesias R., Ramirez M.L., Vazquez-Barquero J.L., Crespo-Facorro B. Prevention of antipsychotic-induced weight gain with early behavioural intervention in first-episode psychosis: 2-year results of a randomized controlled trial. Schizophr. Res. 2010, 116(1):16-19.
2. American Diabetes Association Diagnosis and classification of diabetes mellitus. Diab. Care 2005, 28(Suppl. 1):S37-S42.
3. Arranz B., Rosel P., Ramirez N., Duenas R., Fernandez P., Sanchez J.M., Navarro M.A., San L. Insulin resistance and increased leptin concentrations in noncompliant schizophrenia patients but not in antipsychotic-naive first-episode schizophrenia patients. J. Clin. Psychiatry 2004, 65(10):1335-1342.
4. Blin O., Micallef J. Antipsychotic-associated weight gain and clinical outcome parameters. J. Clin. Psychiatry 2001, 62(Suppl. 7):11-21.
5. Brown S., Inskip H., Barraclough B. Causes of the excess mortality of schizophrenia. Br. J. Psychiatry 2000, 177:212-217.
6. Capasso R.M., Lineberry T.W., Bostwick J.M., Decker P.A., St Sauver J. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophr. Res. 2008, 98(1-3):287-294.
7. Centers for Disease Control and Prevention (CDC) National Center for Health Statistics (NCHS). National Health and Nutrition Examination Survey Data. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention accessed on January 26, 2010. http://www.cdc.gov/nchs/nhanes/nhanes2005-2006/nhanes05_06.htm.
8. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., Jones D.W., Materson B.J., Oparil S., Wright J.T., Roccella E.J. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42(6):1206-1252.
9. Colton C.W., Manderscheid R.W. Congruencies in increased mortality rates, years of potential life lost, and cause of death among public mental health clients in eight states. Prev. Chron. Dis. 2006, 3(2):A42.
10. De Hert M.A., van Winkel R., Van Eyck D., Hanssens L., Wampers M., Scheen A., Peuskens A. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr. Res. 2006, 83(1):87-93.
11. De Hert M., Schreurs V., Vancampfort D., Winkel R.V. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 2009, 8(1):15-22.
12. de Leon J., Diaz F.J. A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors. Schizophr. Res. 2005, 76(2-3):135-157.
13. Enger C., Weatherby L., Reynolds R.F., Glasser D.B., Walker A.M. Serious cardiovascular events and mortality among patients with schizophrenia. J. Nerv. Ment. Dis. 2004, 192(1):19-27.
14. Expert Panel on Detection and Evaluation of Treatment of High Blood Cholesterol in Adults Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285(19):2486-2497.
15. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV Axis I Disorder - Patient Edition (SCID-I/P), Version 2.0. Biometric Research 1995, New York State Psychiatric Institute, New York.
16. Goff D.C., Sullivan L.M., McEvoy J.P., Meyer J.M., Nasrallah H.A., Daumit G.L., Lamberti S., D'Agostino R.B., Stroup T.S., Davis S., Lieberman J.A. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr. Res. 2005, 80(1):45-53.
17. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J. (see endnote) Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J. Am. Coll. Cardiol. 2004, 44(3):720-732.
18. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353(12):1209-1223.
19. Marshall M., Rathbone J. Early intervention for psychosis. Cochrane Database Syst. Rev. 2006, 4:CD004718.
20. Meigs J.B., Wilson P.W., Nathan D.M., D'Agostino R.B., Williams K., Haffner S.M. Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 2003, 52(8):2160-2167.
21. Mueser K.T., Drake R.E., Clark R.E., McHugo G.J., Mercer-McFadden C., Ackerson T.H. A Toolkit for Evaluating Substance Abuse in Persons with Severe Mental Illness 1995, Evaluation center at Human Services Research Institute, Cambridge, MA.
22. National Cholesterol Education Program: Third Report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), accessed on January 26, 2010. http://hp2010.nhlbihin.net/atpiii/calculator.asp?usertype=prof.
23. Newcomer J.W. Comparing the safety and efficacy of atypical antipsychotics in psychiatric patients with co-morbid medical illnesses. J. Clin. Psychiatry 2009, 70(Suppl. 3):30-36.
24. Oriot P., Feys J.L., Mertens de Wilmars S., Misson A., Ayache L., Fagnart O., Gruson D., Luts A., Jamart J., Hermans M.P., Buysschaert M. Insulin sensitivity, adjusted beta-cell function and adiponectinaemia among lean drug-naive schizophrenic patients treated with atypical antipsychotic drugs: a nine-month prospective study. Diab. Metab. 2008, 34(5):490-496.
25. Osborn D.P., Levy G., Nazareth I., Petersen I., Islam A., King M.B. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch. Gen. Psychiatry 2007, 64(2):242-249.
26. Osby U., Correia N., Brandt L., Ekbom A., Sparen P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr. Res. 2000, 45(1-2):21-28.
27. Parks J., Svendsen D., Singer P., Foti M. Morbidity and mortality in people with serious mental illness. National Association of State Mental Health Program Directors (NASMHPD) Medical Directors Council accessed on January 26, 2010. http://www.nasmhpd.org/general_files/publications/med_directors_pubs/Technical%20Report%20on%20Morbidity%20and%20Mortaility%20-%20Final%2011-06.pdf.
28. Patel J.K., Buckley P.F., Woolson S., Hamer R.M., McEvoy J.P., Perkins D.O., Lieberman J.A., Investigators C.A.F.E. Metabolic profiles of second-generation antipsychotics in early psychosis: findings from the CAFE study. Schizophr. Res. 2009, 111(1-3):9-16.
29. Perez-Iglesias R., Crespo-Facorro B., Amado J.A., Garcia-Unzueta M.T., Ramirez-Bonilla M.L., Gonzalez-Blanch C., Martinez-Garcia O., Vazquez-Barquero J.L. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. J. Clin. Psychiatry 2007, 68(11):1733-1740.
30. Perez-Iglesias R., Crespo-Facorro B., Martinez-Garcia O., Ramirez-Bonilla M.L., Alvarez-Jimenez M., Pelayo-Teran J.M., Garcia-Unzueta M.T., Amado J.A., Vazquez-Barquero J.M. Weight gain induced by haloperidol, risperidone and olanzapine after 1year: findings of a randomized clinical trial in a drug-naive population. Schizophr. Res. 2008, 99(1-3):13-22.
31. Ryan M.C., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160(2):284-289.
32. Sengupta S., Parrilla-Escobar M.A., Klink R., Fathalli F., Ng Y.K., Stip E., Baptista T., Malla A., Joober R. Are metabolic indices different between drug-naive, first-episode psychosis patients and healthy controls?. Schizophr. Res. 2008, 102(1-3):329-336.
33. Spelman L.M., Walsh P.I., Sharifi N., Collins P., Thakore J.H. Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diab. Med. 2007, 24(5):481-485.
34. Srihari V.H., Breitborde N.J.K., Pollard J., Tek C., Hyman L., Frisman L.K., McGlashan T.H., Jacobs S., Woods S.W. Public academic partnerships: early intervention for psychotic disorders in a community mental health center. Psychiatr. Serv. 2009, 60(11):1426-1428.
35. Stahl S.M., Mignon L., Meyer J.M. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?. Acta Psychiatr. Scand. 2009, 119(3):171-179.
36. Tarricone I., Ferrari Gozzi B., Serretti A., Grieco D., Berardi D. Weight gain in antipsychotic-naive patients: a review and meta-analysis. Psychol. Med. 2010, 40(2):187-200.
37. Tiihonen J., Lonnqvist J., Wahlbeck K., Klaukka T., Niskanen L., Tanskanen A., Haukka J. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009, 374(9690):620-627.
38. Verma S.K., Subramaniam M., Liew A., Poon L.Y. Metabolic risk factors in drug-naive patients with first-episode psychosis. J. Clin. Psychiatry 2009, 70(7):997-1000.
39. Wilson P.W., D'Agostino R.B., Levy D., Belanger A.M., Silbershatz H., Kannel W.B. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97(18):1837-1847.
40. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., McQueen M., Budaj A., Pais P., Varigos J., Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004, 364(9438):937-952.
41. Zipursky R.B., Gu H., Green A.I., Perkins D.O., Tohen M.F., McEvoy J.P., Strakowski S.M., Sharma T., Kahn R.S., Gur R.E., Tollefson G.D., Lieberman J.A. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. Br. J. Psychiatry 2005, 187:537-543.